Beyond Inc to Acquire Buy Buy Baby Brand Rights Reuniting Baby Retailer with Bed Bath Beyond Oura Health Files Confidentially for IPO as Smart Wearables Market Gains Momentum Grizz Chapman 30 Rock Star Passes Away at 52 Vickers Insider Trading Report Top Buyers and Sellers for May 27 2026 ONGC Q4 Net Profit Surges 46 YoY to Rs 10820 Crore Revenue Up 4 Nostalgia and Speculation Fuel MultiMillion Dollar Pokmon Card Boom SLM Q1 2026 Earnings EPS Surges Past Estimates on Strong Credit and Cost Control CENTA Q1 2026 Earnings EPS Surpasses Estimates by 154 LegalZoom Q1 2026 Earnings EPS Misses Estimates as Stock Declines Kaltura Q1 2026 Earnings EPS Surges Past Estimates as Profitability Improves SY Q1 2026 Earnings NarrowerThanExpected Loss Fails to Lift Sentiment as Revenue Remains Under Wraps Aterian Inc ATER Q3 2025 Earnings Strong EPS Beat Highlights Operational Efficiency Fortinet FTNT Surges 345 as Cybersecurity Momentum Builds Support and Resistance in Focus Uranium Royalty Corp UROY Gains 246 as Nuclear Sentiment Lifts Uranium Exposure CBIZ Inc CBZ Rises 149 as Stock Tests Resistance Near 3352 CocaCola Europacific Partners CCEP Holds Steady Near Support Amid Modest Decline Algoma Steel Group ASTL Edges Higher Holds Above Key 475 Support Level Chinese Dividend Stocks Gain Favor Amid Limited Investment Options DDL Q4 2025 Earnings Positive EPS Reported Amid Mixed Market Reaction Skyworks Solutions SWKS Hits New Lows as Selling Pressure Intensifies ThredUp Q1 2026 Earnings NarrowerthanExpected Loss Lifts Shares Centene Q1 2026 Earnings EPS Surges 56 Above Estimates as Managed Care Segment Shows Strength MASI Q1 2026 Earnings EPS Falls 26 Short of Estimates as Margins Come Under Pressure BBGI Q4 2025 Earnings Significant Loss Reported Shares Rally on Positives SKYH Q4 2025 Earnings Positive EPS Surprise Signals Operational Inflection Point USCB Financial Holdings Inc Q1 2026 Earnings EPS Surpasses Estimates by 548 Amid Steady Performance Processa Pharmaceuticals PCSA Q4 2025 Earnings EPS Misses Estimates by a Wide Margin as PreRevenue Biotech Advances Pipeline